ArticleJournal of visualized experiments : JoVE2016
A Murine Model of Group B Streptococcus Vaginal Colonization.
Article in Journal of visualized experiments : JoVE, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Type 2 diabetes mellitus exacerbates vaginal group BmSphere · 2026Article
- Acquisition of a novel restriction modification system regulates genetic flux and gene expression in the hypervirulent and globally disseminated CC17 lineage of group B Streptococcus.Nucleic acids research · 2026Article
- Article
- Microbiota-dependent interferon-λ controls immunity of the uterus and maternal-fetal interface.Research square · 2026Article
- Bacteriophage-mediated reduction of uropathogenicInfection and immunity · 2026Article
- Type 2 diabetes mellitus exacerbates vaginal group BbioRxiv : the preprint server for biology · 2026Article
- A murine model of adult gastrointestinal colonization by Group BInfection and immunity · 2026Article
- Microbiota-dependent IFN-L controls uterine and placental immunity.bioRxiv : the preprint server for biology · 2026Article
- New Strategies for Preventing Perinatal Group B Streptococcus (GBS) Infections.Pathogens (Basel, Switzerland) · 2025Review
- Advanced Vaginal Nanodelivery of Losartan Potassium via PEGylated Zein Nanoparticles for Methicillin-ResistantPharmaceutics · 2025Article
- Bacteriophage-mediated reduction of uropathogenicbioRxiv : the preprint server for biology · 2025Article
- Article
- Genome-wide mutagenesis identifies factors involved in MRSA vaginal colonization.Cell reports · 2025Article
- Group B streptococcal infections in pregnancy and early life.Clinical microbiology reviews · 2025Review
- TSST-1 promotes colonization ofInfection and immunity · 2025Article
- Preclinical validation of electrospun fibers to achieve vaginal colonization byFrontiers in bacteriology · 2025Article
- Re-framing the importance of Group BInfection and immunity · 2024Review
- A group B streptococcal type VII secreted LXG toxin mediates interbacterial competition and colonization of the female genital tract.bioRxiv : the preprint server for biology · 2024Article
- Diet influences community dynamics following vaginal group B streptococcus colonization.Microbiology spectrum · 2024Article
- Gestational diabetes augments group B Streptococcus infection by disrupting maternal immunity and the vaginal microbiota.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Streptococcus agalactiae (group B Streptococcus, GBS), is a Gram-positive, asymptomatic colonizer of the human gastrointestinal tract and vaginal tract of 10 - 30% of adults. In immune-compromised individuals, including neonates, pregnant women, and the elderly, GBS may switch to an invasive pathogen causing sepsis, arthritis, pneumonia, and meningitis. Because GBS is a leading bacterial pathogen of neonates, current prophylaxis is comprised of late gestation screening for GBS vaginal colonization and subsequent peripartum antibiotic treatment of GBS-positive mothers. Heavy GBS vaginal burden is a risk factor for both neonatal disease and colonization. Unfortunately, little is known about the host and bacterial factors that promote or permit GBS vaginal colonization. This protocol describes a technique for establishing persistent GBS vaginal colonization using a single β-estradiol pre-treatment and daily sampling to determine bacterial load. It further details methods to administer additional therapies or reagents of interest and to collect vaginal lavage fluid and reproductive tract tissues. This mouse model will further the understanding of the GBS-host interaction within the vaginal environment, which will lead to potential therapeutic targets to control maternal vaginal colonization during pregnancy and to prevent transmission to the vulnerable newborn. It will also be of interest to increase our understanding of general bacterial-host interactions in the female vaginal tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.